Ocuphire to Present at Five Upcoming Investor/Industry Conferences

Nov 21, 2022

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

Nov 7, 2022

Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update

Nov 4, 2022

Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)

Nov 2, 2022

Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting

Oct 24, 2022

Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

Oct 7, 2022

Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease

Oct 6, 2022

Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team

Sep 29, 2022

Ocuphire Announces Upcoming Presentations at European Forum 2022, [email protected] 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

Sep 15, 2022

Ocuphire Pharma Receives PDUFA Fee Waiver for Nyxol New Drug Application from FDA

Sep 12, 2022